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Abstract
Background. Kidney transplantation generally improves
long-term survival in patients with end-stage renal dis-
ease. However, in patients older than 70 years of age,
only limited data are available that directly compare
the potential survival benefit of transplantation versus
dialysis.
Methods. All patients aged above 70 years who started
dialysis between 1990 and 2005 and were waitlisted for
kidney transplantation were included in the study. They
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1680 K. Heldal et al.were categorized according to time periods of inclusion
(1990–99 vs 2000–05). Survival rates of altogether 286 di-
alysis patients were analyzed with a Kaplan–Meier model,
as well as with a time-dependent Cox model. Comparisons
w e r em a d eb e t w e e nt h o s ew h or e c e i v e dat r a n s p l a n ta n d
thosewhodidnot,andfurtherbetweenthetwotimeperiods.
Results. Median age at inclusion was 73.6 years (interquar-
tile range 72.3–75.6). Two hundred and thirty-three patients
(81%) received a kidney transplant during follow-up.
Transplant recipients experienced an increased mortality
in the first year after transplantation when compared to
waitlisted patients. Patients starting dialysis between 1990
and 1999 had no significant long-term benefit of transplan-
tation; HR for death 1.01 (0.58–1.75). In contrast, therewas
a substantial long-term benefit of transplantation among
those starting dialysis after 2000; HR for death 0.40
(0.19–0.83), P = 0.014.
Conclusions. Survival after kidney transplantation in pa-
tients over 70 years has improved during the last decade
and offers a survival advantage over dialysis treatment.
Our experience supports the use of kidney transplantation
in this age group if an increased early post-operative risk is
accepted. This transplant policy may be challenged for pri-
ority reasons.
Keywords: dialysis; elderly patients; epidemiology; kidney
transplantation; patient survival
Introduction
Elderly patients are by far the fastest growing population
requiring renal replacement therapy (RRT) both in Europe
and in the USA [1–4]. Patients above 65 years of age con-
stitute >15% of the waitlisted patients in the USA in 2009
[5] compared to 7% in 1997 [3]. Kidney transplantation is
in general regarded as the treatment of choice both with
respect to survival, quality of life and costs [6–12]. If suc-
cessful, the advantages of kidney transplantation appear to
be the same for elderly as for young recipients [13–19], but
data are limited for kidney transplant recipients above 70
years of age.
Most reports comparing survival of kidney transplant re-
cipients and patients on dialysis are based on registry data
from multiple centers and have major limitations. The se-
lection and work-up procedure of transplant recipients vary
between centers and the same goes for choice of immuno-
suppressive protocols and follow-up procedures. Dialysis
treatment also differs significantly between centers. Such
variations may have substantial impact on patient survival.
Obviously, it is unethical to perform a prospective, random-
ized controlled trial comparing dialysis and transplantation
in eligible potential transplant recipients. Rikshospitalet is
the only transplant center in Norway, serving ∼4.8 million
inhabitants. All candidates for transplantation haveto fulfill
the same criteria for acceptance, and the recipients receive a
uniform treatment and follow-up after transplantation. Dur-
ing the last 20 years, a relatively large number of patients
a b o v et h ea g eo f7 0h a v eb e e nt r a n s p l a n t e da to u rc e n t e r
[13]. The primary objective of the present study was to as-
sess the effect of kidney transplantation versus continued
dialysis on mortality in recipients that started dialysis treat-
ment attheage of70 yearsor more and fulfilled therequire-
ments to receive a kidney allograft. A secondary objective
was to compare the post-transplant outcome related to dif-
ferent time periods, reflecting different immunosuppressive
protocols that were used during the study period.
Materials and methods
Study design
Data of all patients aged 70 years and older, not previously trans-
planted, who had started dialysis from 1990 throughout 2005 and were
accepted at the transplantation waitlist, were retrieved from the Norwe-
gian Renal Registry. Survival analyses were performed comparing
those patients remaining on the waiting list with those who were trans-
planted. For patients being transplanted, additional data concerning co-
morbidity at the time of transplantation, immunosuppressive treatment
and other data related to the transplant procedure were retrieved from
the hospital records and the Norwegian Renal Registry. Start of study
was set at the time of waitlisting for deceased donor transplantation, at
the time of acceptance for living donor transplantation or at start of
dialysis (latest of those). All patients were followed until death or
end of study (1 May 2008).
Standard immunosuppressive protocol following kidney transplanta-
tion at our center was changed during the study period. In the first era
(1990–99), all recipients received triple immunosuppression with cyclo-
sporine, azathioprine and steroids. From 2000, azathioprine (AZA) was
stopped and intravenous basiliximab (2000) was added. From 2001, all
recipients received cyclosporine, steroids and mycophenolate mofetil
(MMF). Therefore, we divided the study population into two groups ac-
cording to the year of dialysis start (1990–99 versus 2000–05). In addition,
we performed Kaplan–Meier survival analysis in those patients eventually
Table 1. Baseline characteristics of the study population
All (n = 286) Transplant (n = 233) Waitlist (n = 53) P value
Months on dialysis before waitlisting; median (range) 7.0 (0–40.6) 6.8 (0–40.2) 8.0 (0.6–40.6) NS
Age at start of dialysis; median (range) 73.1 (70.0–81.0) 72.9 (70.0–81.0) 73.6 (70.2–80.2) NS
Age at entering waitlist; median (range) 73.6 (69.5–82.1) 73.4 (69.5–82.0) 74.5 (71.0–82.1) NS
Haemodialysis/peritoneal dialysis 77%/23% 76%/24% 85%/15% NS
Female gender 85 (30%) 75 (32%) 10 (19%) NS
Diabetes nephropathy 12 (4%) 7 (3%) 5 (9%) 0.05
Glomerulonephritis 88 (31%) 69 (30%) 19 (36%) NS
Pyelonephritis 28 (10%) 25 (11%) 3 (6%) NS
Familiar/hereditary renal disease 27 (9%) 22 (9%) 5 (9%) NS
Vascular diseases 109 (38%) 91 (39%) 18 (34%) NS
Other/unknown 22 (8%) 19 (8%) 3 (6%) NS
P values indicate comparison of patients eventually transplanted with those remaining on the waitlist never receiving a transplant.
Benefit of kidney transplantation beyond 70 years of age 1681receiving a transplant, comparing patients transplanted between 1990 and
1999 with those who were transplanted between 2000 and 2008.
The dialysis patients received either haemodialysis or peritoneal dial-
ysis or a combination of these, simultaneously or in sequence. The vast
majority of patients were treated in haemodialysis, and we have analyzed
peritoneal dialysis and haemodialysis together as one group in the statis-
tical analysis.
Statistics
Two-sided unpaired t-test or Mann–Whitney test was used as appropriate
to compare groups. Fisher's exact test was used to analyze binary data.
Survival data were assessed with the Kaplan–Meier method. Survival in
the waitlist group was counted from start of dialysis or time of waitlisting
(latest of those) to death or censoring due to transplantation or end of
study (1 May 2008). Survival in the transplant group was counted from
the time of transplantation to death or censoring due to end of study (1
May 2008). Furthermore, the data were analyzed in a time-dependent Cox
model [20], censoring patients from the waitlist group at time of trans-
plantation. In the time-dependent Cox model, the waitlist group was cho-
sen as indicator versus the transplant group. Logistic regression analysis
was used to identify risk factors for acute rejection episodes. The analyses
were implemented using SPSS
® 15.0.
Results
From 1990 throughout 2005, a total of 1979 patients aged
70 or more started RRT in Norway. Three hundred and
twenty-two patients (16%) were accepted at the transplan-
tation waitlist. Thirty-six patients (11%) received a trans-
plant pre-emptively. The remaining 286 patients were
accepted for transplantation and placed on the waiting list.
Median age at start of dialysis was 73.1 years (interquartile
range 71.4–74.7). Median age at inclusion was 73.6 years
(72.3–75.6). Two hundred and thirty-three patients (81%)
received a transplant during the observation period. Thirty-
seven patients (16%) received a kidney from a living do-
Table 2. Baseline characteristics all patients placed on the transplant waitlist
1990–99 (n = 173) 2000–05 (n = 113) P value
Months on dialysis before waitlisting; median (range) 5.9 (0–40.6) 8.9 (0–40.4) 0.001
Age at start of dialysis; median (range) 73.1 (70.0–81.0) 73.0 (70.0–81.0) NS
Age at entering waitlist; median (range) 73.6 (69.5–81.3) 73.6 (70.1–82.1) NS
Haemodialysis/peritoneal dialysis 82%/18% 70%/30% 0.02
Female gender 56 (32%) 29 (26%) NS
Diabetes nephropathy 5 (3%) 7 (6%) NS
Glomerulonephritis 67 (39%) 21 (19%) <0.001
Pyelonephritis 20 (12%) 8 (7%) NS
Familiar/hereditary renal disease 16 (9%) 11 (10%) NS
Vascular diseases 48 (28%) 61 (54%) <0.001
Other/unknown 17 (10%) 5 (4%) NS
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Fig. 1. Kaplan–Meier survival plot: survival of waitlisted patients and patients receiving a kidney transplant. Start of dialysis: 1990–2005. Patients were
censored from the waitlist group at the time of transplantation.
1682 K. Heldal et al.nor. Median age at time of transplantation was 74.3 years
(interquartile range 73.1–76.4). Baseline data comparing
those patients receiving a transplant with those who did
not are presented in Table 1. Baseline data comparing
the two time eras are shown in Table 2. No patient was lost
to follow-up.
Survival of patients placed on the transplantation waitlist
Among patients remaining on the transplantation waitlist
(n = 286), median survival from waitlisting was 3.4
(3.0–3.8) years compared to 4.8 (3.8–5.9) years in the
transplant group (n = 233). Five-year survival was 31%
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Fig. 2. Kaplan–Meier survival plot: survival of waitlisted patients and patients receiving a kidney transplant. Start of dialysis: 1990–99. Patients were
censored from the waitlist group at the time of transplantation.
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Fig. 3. Kaplan–Meier survival plot: survival of waitlisted patients and patients receiving a kidney transplant. Start of dialysis: 2000–05. Patients were
censored from the waitlist group at the time of transplantation.
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(Figure 1). In the time-dependent Cox model, we found no
significant difference between the transplant and waitlist
groups, even though there was a trend towards an overall
reduced risk of death for those who were transplanted;
hazard ratio (HR) 0.78, 95% confidence interval (CI)
0.52–1.18, P = 0.25 [adjusted for age, sex, primary kidney
disease, type of center where dialysis was initiated (uni-
versity vs not university hospital), time on dialysis before
waitlisting and dialysis modality]. The variables identified
as significant/near significant risk factors for acute rejec-
tion episodes were immunosuppression with AZA versus
MMF; odds ratio (OR) 2.79, 95% CI 1.56–5.38, P =
0.002, any HLA-DR mismatch; OR 2.04, 95% CI 1.11–
Table 3. Characteristics of kidney transplant recipients by period of transplantation
1990–99 (n = 116) 2000–07 (n = 117) P value
Age; median (range) 74.2 (70.2–81.5) 74.6 (70.2–82.9) NS
Female recipient 39 (34%) 36 (31%) NS
Months on dialysis; median (range) 14.0 (1.0–47.0) 12.0 (0.6–71.0) NS
Haemodialysis/peritoneal dialysis 89%/11% 69%/31% <0.001
Donor age; median (range) 50.0 (14–78) 57.8 (4–86) <0.001
Donor age >60 years 30 (26%) 55 (47%) 0.001
Living donor 19 (16%) 18 (15%) NS
Female donor 50 (43%) 59 (50%) NS
CMV positive donor 92 (80%) 86 (74%) NS
Any HLA-A mismatch 86 (74%) 93 (79%) NS
Any HLA-B mismatch 98 (84%) 102 (87%) NS
Any HLA-DR mismatch 69 (59%) 56 (48%) NS
PRA pos recipient 8 (7%) 5 (4%) NS
Pre-transplant ischaemic heart disease 36 (31%) 40 (34%) NS
Pre-transplant diabetes mellitus 10 (9%) 16 (14%) NS
Diabetes nephropathy 3 (3%) 4 (3%) NS
Charlson Comorbidity Index; median (range) 3 (2–7) 3 (2–10) NS
Cold ischaemia time (hours); median (range) 14 (1–28) 12 (1–28) NS
Cyclosporine 116 (100%) 108 (92%) 0.005
AZA 96 (83%) 1 (1%) <0.001
MMF 4 (3%) 104 (89%) <0.001
Delayed graft function 19 (17%) 37 (32%) 0.009
Proportion of deaths because of infection 29 (26%) 12 (32%) NS
Rejection within 90 days 58 (50%) 28 (24%) <0.001
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Fig. 4. Survival of kidney transplant recipients according to transplant era.
1684 K. Heldal et al.3.78, P = 0.023, donor age over 60 years; OR 2.05, 95%
CI 1.09–3.86, P = 0.025 and cytomegalovirus (CMV)
positive donor; OR 2.11, 95% CI 0.98–4.57, P = 0.058.
The following other variables were also tested inthemul-
tivariate logistic regression model without significant im-
pact: recipient age, living versus deceased donor, panel
reactive antibody (PRA) positive recipient, any HLA-A
mismatch, any HLA-B mismatch and cold ischemia time.
Survival according to year of transplantation/start of
dialysis
When categorizing the study population into two groups
according to time for start of dialysis, there was no appar-
ent benefit of transplantation in the first era (1990–99, n =
173); HR 1.01 (0.58–1.75). In contrast, there was a marked
and significant benefit of transplantation among those
starting dialysis between 2000 and 2005 (n = 113); HR
0.40 (0.19–0.83), P = 0.014. When compared to continued
dialysis treatment, the transplant recipients of both eras
had increased mortality in the first 12 months after trans-
plantation. The subsequent reduction in mortality leads to
a survival benefit starting 3.5 years after transplantation in
the first era (Figure 2) and after ∼2.5 years in the last era
(Figure 3).
The transplant recipients were categorized into sub-
groups according to time era they were transplanted
(1990–99, n = 116 vs 2000–07, n = 117). Baseline char-
acteristics of the two transplant cohorts are presented in
Table 3. There was no difference between the two
groups with respect to comorbidity described by Charl-
son Comorbidity Index [21], proportion receiving a liv-
ing donor kidney or in HLA-A, -B or -DR mismatch.
The median survival after transplantation increased from
3.7 (3.0–4.4) years in 1990–99 to >6.7 years in 2000–07
(Figure 4).
Median survival after time of waitlisting did not change
in the waitlist group according to start of dialysis; 3.4 (3.1–
3.7) years in 1990–99 (n = 173) versus 3.1 (1.8–4.4) years
in 2000–05 (n = 113). Survival after 1, 3 and 5 years from
transplantation in the transplant group and from start of di-
alysis in thewaitlist group are presented in Table 4. Twenty-
one recipients (18%) transplanted between 1990 and
1999 died in the first 6 months after the transplantation
compared to nine recipients (8%) transplanted between
2000 and 2007 (P = 0.02). Among the 21 deaths in the
first cohort, 10 were related to infection (five pneumonias,
four septicemias and one case of peritonitis), all had re-
ceived rejection treatment. All nine deaths in the last co-
hort were caused by infection (four pneumonias, four
septicemias and one unspecified infection), four of them
received rejection treatment.
Discussion
The results support the notion that, at least during the last
10 years, transplantation appears beneficial and improves
patient survival in patients beyond 70 years of age. A pre-
requisite is a proper transplant work-up of the patients to
ensure overall medical fitness for such a procedure. The
number of elderly patients requiring RRT increases world-
wide. This trend is likely to continue. With current short-
age of organs, it may be difficult to find arguments in favor
of using a donor kidney in a patient with limited life ex-
pectancy, such as the elderly patient. Our data may justify
the use of kidney transplantation in patients older than
70 years of age. Apart from a survival advantage, it has
generally been accepted that both quality of life and cost
are improved by transplantation, but these factors were not
the scope of the present study. One may argue that patients
at high age should not be offered a kidney transplant due to
organ shortage striking many young patients awaiting kid-
ney transplantation. However, in our country, the active
policy of transplantation in high age has not lead to an in-
crease in the waitlist.
Elderly kidney transplant recipients had an increased
risk of death during the first year after transplantation
compared to the age matched dialysis patients remaining
on the waiting list. This is in line with what has been de-
scribed in previous registry analyses [15,16]. There was no
survival benefit in the first time era in contrast to a sub-
stantial benefit in the last era from 2000. One possible ex-
planation was the change of immunosuppressive protocol
in 2000. It is well recognized that acute rejection during
the first 3 months after transplantation is a major risk fac-
tor for premature death in elderly kidney recipients [22].
When AZA was replaced by basiliximab or MMF, the fre-
quency of acute rejection episodes was reduced by 50%.
The mortality risk remained increased in the immediate
post-operative period and became comparable with the risk
of death on dialysis during the first year, before decreasing
considerably to a beneficial long-term effect. A similar
finding was reported in the landmark study published by
Wolfe et al. where they noted 61% lower risk of death at
18 months after transplantation compared with dialysis for
patients aged 60–74 years [9].
Organs from old donors are usually allocated to elderly
recipients. It has been proposed that elderly recipients, due
to a less active immune system, are less prone to develop
Table 4. Survival of transplant recipients and dialysis patients on the waitlist
1990–99 2000 →
n 1 year 3 years 5 years n 1 year 3 years 5 years P value
Transplant 116 79% 60% 39% 117 89% 74% 64% <0.001
Waitlist 173 93% 66% 29% 113 98% 56% 33% NS
Survival was counted from time of transplantation (transplant) or from start of dialysis (waitlist).
Benefit of kidney transplantation beyond 70 years of age 1685acute cellular rejection compared to younger recipients.
However, in a Dutch study published in 2001, the authors
claim that older kidneys are more immunogenic and there-
fore require more intense immunosuppression [23]. In the
first protocol of the Eurotransplant Senior Program (ESP),
kidneys were allocated locally without HLA matching to
obtain short ischaemia time [24,25]. This procedure re-
sulted in a high percentage of acute rejection. In a recent
analysis of ESP data, Pratschke et al. describe an initially
pronounced immune response in elderly recipients receiv-
ing grafts from elderly donors [26]. In the new protocol
(ESDP), full HLA-DR compatibility is introduced in the
allocation protocol to reduce the risk of rejection episodes
and thereby reduce the need for rejection therapy and the
additional risk of complications due to infection [27]. Our
results support the view that immunologic factors are im-
portant, especially in elderly transplant recipients. In addi-
tion to adequate HLA compatibility, our results also
implicate that it is important for elderly recipients to re-
ceive adequate immunosuppression early to reduce acute
rejection episodes. Too strong immunosuppressive therapy
may cause infectious complications. The relative risk of
death of transplant recipients compared to dialysis was
higher in the first 6 months in the cohort who received
the strongest immunosuppressive regimen, and all deaths
were caused by infections. However, the absolute number
of deaths in the first 6 months was lower among recipients
transplanted between 2000 and 2007, and the absolute
number of deaths related to infections was almost the same
in the periods of 1990–99 and 2000–07.
High donor age and increased time on dialysis before
transplantation have been shown to be risk factors for poor
outcome, especially in elderly recipients [22]. In the pres-
ent study, we found no difference regarding time on dial-
ysis, but both the age of the donor and the proportion of
donors older than 60 years were significantly higher in
2000–07 (Table 3). The prevalence of delayed graft func-
tion was considerably higher in the last era. Despite the
negative influence of these variables, the survival was sub-
stantially better in the last era, supporting the proposal that
adequate immunosuppression to avoid rejection episodes
is extremely important in the elderly recipients.
Initially there were stringent acceptance criteria to
chronic dialysis therapy and to be listed for a kidney trans-
plant. Gradually these criteria have been loosened, and to-
day we have very few absolute contraindications to RRT.
This has led to an overall increase in age and comorbidity
of those on the waiting list. Transplantation of elderly pa-
tients is a serious ethical issue in the context of organ
shortage. The dilemma arises when the allocation of a kid-
ney to the benefit of an elderly person inevitably does
‘harm’ to a young person, who therefore, does not receive
the transplant and continues to wait for an appropriate or-
gan. On the other hand, elderly patients with end-stage re-
nal disease (ESRD) are more likely to die on thewaiting list
[28], and it is therefore important to reduce thewaiting time
as much as possible. It may be possible to increase the or-
gan pool by increasing the number of extended criteria do-
nors (ECD). Accepting and transplanting kidneys from
even older donors to elderly recipients is one opportunity
[24,25,29,30], and in a recent publication from our center,
we have demonstrated that kidneys from donors older than
75 could be used with acceptable outcomes in elderly reci-
pients [31]. A policy like this could make it possible to al-
locate ECD kidneys to elderly recipients on the deceased
donor waiting list and thereby reduce their time on dialysis.
Giving possibly ‘lower-quality’ organs to elderly recipients
raises further moral and ethical arguments, but an ‘old-for-
old’ policy has already been adopted in several countries
and elderly transplant candidates are among those who
are most likely to receive optimal benefits from ECD
kidneys [32].
Some methodological issues deserve attention. Firstly,
all patients in the transplant group have been treated with
dialysis for some time prior to transplantation. Therefore, in
the Kaplan–Meier analysis, transplant patients have longer
total time on RRT than the patients in the waitlist group.
This may bias the results of the Kaplan–Meier analysis in
favor of those not being transplanted. Secondly, as a result
of our study design, all patients, transplanted or not, have
met the same selection criteria. There was no difference
between the transplant and waitlist groups with respect
to age at waitlisting or time from start of dialysis to wait-
listing. However, there was a trend towards a higher pro-
portion of female patients and patients on peritoneal
dialysis in the transplant group. In addition, there was a
significant higher prevalence of diabetes nephropathy
among those who were not transplanted. Despite this,
we regard the differences between the groups to be mi-
nor, especially in the retrospective study setting. In addi-
tion, the study is from a single transplant center. This
could also be regarded as a limitation to the study. It
may be claimed that the study describes the results of a
transplant policy not applicable to any other countries or
transplant centers. However, the fact that all patients have
been treated at the same transplant center, following the
same criteria for acceptance and the same standard immu-
nosuppressive protocol, makes the data robust and
strengthens the study. Furthermore, the robust and com-
plete national registry of RRT patients has also made it
possible to complete the study without any patient lost
to follow-up.
Conclusion
In conclusion, elderly patients beyond 70 years of age on
dialysis treatment, who fulfill the established medical cri-
teria for waitlisting, will benefit from kidney transplanta-
tion compared to continuing dialysis. There is a marked
long-term survival benefit which is highly significant after
the introduction of newer immunosuppressive protocols.
Transplantation should be preferred as the treatment of
choice also for elderly patients with ESRD given a suffi-
cient supply of organs.
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